Skip to content

RxSight, Inc. RXST Restricted Cash

Restricted Cash at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.61M0.0%
Bausch + Lomb logo
Bausch + LombBLCO
$11M-15.4%
Glaukos logo
GlaukosGKOS
$3.83M-19.0%

Other financials

Income statement

See full
Revenue$30.9M-18.5%
Gross profit$23.5M-17.1%
Operating income-$17.8M-67.0%
Net income-$15.9M-93.9%
EPS (diluted)-$0.38-90.0%

Balance sheet

See full
Cash & equivalents$17.6M-37.2%
Total debt$10.8M-10.1%
Total equity$267.3M-4.3%
Total assets$304.0M-2.9%

Cash flow

See full
Operating cash flow-$10.9M-23.3%
CapEx$759.0K+32.0%
Free cash flow-$11.7M-23.8%

Valuation

See full
Market cap$232.23M-56.8%
Enterprise value$225.49M-55.7%
P/S1.8×-1.8×

Profitability

See full
Gross margin77%+5.1pp
Operating margin-43.4%+128pp
Net margin-36.6%-867pp
FCF margin-16.9%+4.9pp

Returns & leverage

See full
Return on equity-17.1%+12.6pp
Debt / equity0.0×
Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: RxSight, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RxSight, Inc.'s restricted cash?
RxSight, Inc. (RXST) reported restricted cash of $750K in Q1 2026.
How has RxSight, Inc.'s restricted cash changed year-over-year?
RxSight, Inc.'s restricted cash decreased by 0.0% year-over-year, from $750K to $750K.
What is the long-term trend for RxSight, Inc.'s restricted cash?
Over 5 years (2020 to 2025), RxSight, Inc.'s restricted cash has grown at a 10.2% compound annual growth rate (CAGR), from $461K to $750K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.